EU Approves Merck’s Keytruda, Chemo Combo for Lung Cancer

Merck announced Thursday that the European Commission has approved the use of its anti-PD-1 therapy Keytruda, in combination with platinum-containing chemotherapy, for resectable non-small cell lung cancer first as a neoadjuvant treatment and then continued as a monotherapy afterwards.